Can TMAO reduce endothelial nitric oxide bioavailability and promote vascular inflammatory and prothrombotic signaling?

TMAO (trimethylamine N-oxide), a gut-microbiome–linked metabolite, has credible experimental effects on vascular biology. The evidence is strongest for cellular inflammatory and platelet effects; human clinical causality remains less certain.

Endothelial and inflammatory effects

• Nitric-oxide signaling: Chronic TMAO exposure in mice impaired endothelium-dependent, NO-mediated vasodilation, accompanied by increased vascular superoxide; the antioxidant TEMPOL reversed this dysfunction. In endothelial cells, 24-hour exposure reduced ATP-evoked calcium signaling, eNOS Ser1179 phosphorylation, and NO release.
• Human observations are directionally consistent: higher circulating TMAO correlated with lower brachial flow-mediated dilation in healthy adults and in stable angina. Ascorbic acid restored dilation in older participants, supporting oxidative stress as a contributor. However, these associations do not establish that TMAO itself caused impaired endothelial function.
• Inflammatory activation: Endothelial and vascular smooth-muscle experiments show activation of MAPK/NF-κB signaling, cytokines, adhesion molecules, and leukocyte adhesion. TMAO has also induced mitochondrial ROS, reduced SIRT3–SOD2 signaling, activated the NLRP3 inflammasome and caspase-1, and increased monocyte adhesion.

Prothrombotic mechanisms

• TMAO amplifies agonist-evoked platelet intracellular calcium release, activation, and aggregation in human platelet experiments.
• Dietary TMAO or choline increased arterial thrombosis potential in mice; germ-free and microbiota-transfer studies support a microbiota-dependent pathway. In healthy humans, choline-associated rises in TMAO were directionally linked to greater platelet responsiveness, not clinical thrombotic events.

Clinical interpretation

• Observational associations between higher TMAO and ASCVD can weaken after accounting for kidney function and appear stronger with reduced eGFR, making confounding by renal function, diet, microbiome composition, and comorbidity important.
• Bottom line: TMAO can plausibly reduce endothelial NO bioavailability and promote vascular inflammatory and platelet-centered prothrombotic signaling, particularly with sustained exposure. These mechanisms are well supported experimentally, but evidence that TMAO independently causes human thrombosis or cardiovascular events remains unproven.